alexandrumagurean / iStockphoto.com
A proposed change to supplementary protection certificate (SPC) rules in the EU could lead to the development of less innovative medicines, according to the Irish Pharmaceutical Healthcare Association (IPHA).
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
SPCs, supplementary protection certificates, patent, generics, Irish Pharmaceutical Healthcare Association, IPHA, The Irish Times, European Commission, EU